» Articles » PMID: 33303695

Mitochondria As a Novel Target for Cancer Chemoprevention: Emergence of Mitochondrial-targeting Agents

Overview
Specialty Oncology
Date 2020 Dec 11
PMID 33303695
Citations 20
Authors
Affiliations
Soon will be listed here.
Abstract

Cancer chemoprevention is the most effective approach to control cancer in the population. Despite significant progress, chemoprevention has not been widely adopted because agents that are safe tend to be less effective and those that are highly effective tend to be toxic. Thus, there is an urgent need to develop novel and effective chemopreventive agents, such as mitochondria-targeted agents, that can prevent cancer and prolong survival. Mitochondria, the central site for cellular energy production, have important functions in cell survival and death. Several studies have revealed a significant role for mitochondrial metabolism in promoting cancer development and progression, making mitochondria a promising new target for cancer prevention. Conjugating delocalized lipophilic cations, such as triphenylphosphonium cation (TPP+), to compounds of interest is an effective approach for mitochondrial targeting. The hyperpolarized tumor cell membrane and mitochondrial membrane potential allow for selective accumulation of TPP conjugates in tumor cell mitochondria versus those in normal cells. This could enhance direct killing of precancerous, dysplastic, and tumor cells while minimizing potential toxicities to normal cells.

Citing Articles

Renal-clearable and tumor-retained nanodots overcoming metabolic reprogramming to boost mitochondrial-targeted photodynamic therapy in triple-negative breast cancer.

Yao D, Wang Y, Dong X, Chen Y, Ji D, Zou R J Nanobiotechnology. 2025; 23(1):195.

PMID: 40059207 PMC: 11892270. DOI: 10.1186/s12951-025-03264-7.


Nano-Radiopharmaceuticals in Colon Cancer: Current Applications, Challenges, and Future Directions.

Alkatheeri A, Salih S, Kamil N, Alnuaimi S, Abuzar M, Abdelrahman S Pharmaceuticals (Basel). 2025; 18(2).

PMID: 40006069 PMC: 11859487. DOI: 10.3390/ph18020257.


PTPMT1 inhibition induces apoptosis and growth arrest of human SCLC cells by disrupting mitochondrial metabolism.

Liu X, Sun Y, Gao C, Sun H, Tian F, Xiao F Transl Cancer Res. 2025; 13(12):6956-6969.

PMID: 39816544 PMC: 11730198. DOI: 10.21037/tcr-2024-2379.


Synthetic Approaches Toward Phosphorus-Containing BODIPY and Squaraine Dyes: Enhancing Versatility of Small-Molecule Fluorophores.

Favret J, Dzyuba S Molecules. 2025; 30(1.

PMID: 39795173 PMC: 11721786. DOI: 10.3390/molecules30010116.


NSAID targets SIRT3 to trigger mitochondrial dysfunction and gastric cancer cell death.

Debsharma S, Pramanik S, Bindu S, Mazumder S, Das T, Pal U iScience. 2024; 27(4):109384.

PMID: 38550981 PMC: 10972828. DOI: 10.1016/j.isci.2024.109384.


References
1.
Ma Y, Temkin S, Hawkridge A, Guo C, Wang W, Wang X . Fatty acid oxidation: An emerging facet of metabolic transformation in cancer. Cancer Lett. 2018; 435:92-100. PMC: 6240910. DOI: 10.1016/j.canlet.2018.08.006. View

2.
Fischer K, Hoffmann P, Voelkl S, Meidenbauer N, Ammer J, Edinger M . Inhibitory effect of tumor cell-derived lactic acid on human T cells. Blood. 2007; 109(9):3812-9. DOI: 10.1182/blood-2006-07-035972. View

3.
Gazzano E, Lazzarato L, Rolando B, Kopecka J, Guglielmo S, Costamagna C . Mitochondrial Delivery of Phenol Substructure Triggers Mitochondrial Depolarization and Apoptosis of Cancer Cells. Front Pharmacol. 2018; 9:580. PMC: 5994430. DOI: 10.3389/fphar.2018.00580. View

4.
Li W, Wang Z, Hao S, He H, Wan Y, Zhu C . Mitochondria-Targeting Polydopamine Nanoparticles To Deliver Doxorubicin for Overcoming Drug Resistance. ACS Appl Mater Interfaces. 2017; 9(20):16793-16802. DOI: 10.1021/acsami.7b01540. View

5.
Moreira P, Custodio J, Moreno A, Oliveira C, Santos M . Tamoxifen and estradiol interact with the flavin mononucleotide site of complex I leading to mitochondrial failure. J Biol Chem. 2006; 281(15):10143-52. DOI: 10.1074/jbc.M510249200. View